August 11, 2014

Data Demonstrates F-18 Flutemetamol PET Indicates Progression From Amnestic Mild Cognitive Impairment to Alzheimer’s

New study data presented at the Alzheimer’s Association Intl. Conference 2014 (AAIC) showed that a positive [18F]flutemetamol positron emission tomography (PET) scan for brain amyloid was a highly significant predictor of progression from amnestic Mild Cognitive Impairment (aMCI) to probable Alzheimer’s disease (pAD). Those with positive [18F]flutemetamol scans were approximately 2.5 times more likely to convert to pAD than those with negative scans. The ability of positive [18F]flutemetamol PET images to identify aMCI patients at higher risk of progressing to AD could potentially allow for better patient evaluation and management. {read more here}